What does PHARMAPLUS ROCOURT do?

PHARMAPLUS ROCOURT is a pharmacy in Liège. Private Limited, started on 30 March 1979, 1 establishment.

What is the address of PHARMAPLUS ROCOURT?

The registered office of PHARMAPLUS ROCOURT is located at Chaussée de Tongres 431, 4000 Liège.

Is PHARMAPLUS ROCOURT still active?

Yes. According to the CBE (30 October 2026) PHARMAPLUS ROCOURT is active, legal situation “Normale toestand”, started on 30 March 1979.

Is PHARMAPLUS ROCOURT registered on Peppol?

Yes, PHARMAPLUS ROCOURT is registered on the Peppol network with ID 0208:0419680693.

What is the enterprise number of PHARMAPLUS ROCOURT?

The enterprise number of PHARMAPLUS ROCOURT is BE0419680693.

When was PHARMAPLUS ROCOURT founded?

PHARMAPLUS ROCOURT was founded on 30 March 1979.

Who are the directors of PHARMAPLUS ROCOURT?

According to the 2025 annual accounts, the directors of PHARMAPLUS ROCOURT are: PHARMA INVEST MANAGEMENT SRL.

Is PHARMAPLUS ROCOURT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 March 1979; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMAPLUS ROCOURT make in 2025?

PHARMAPLUS ROCOURT posted a profit after taxes of € 32,216 in financial year 2025.

What is the revenue of PHARMAPLUS ROCOURT?

As a small company, PHARMAPLUS ROCOURT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 290,836.

How much does an employee at PHARMAPLUS ROCOURT earn?

The average wage cost per full-time employee at PHARMAPLUS ROCOURT was € 66,100 in 2025: staff costs of € 217,973 for 3.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMAPLUS ROCOURT have?

According to the 2025 annual accounts, PHARMAPLUS ROCOURT has 3.3 full-time equivalents (FTE).

PHARMAPLUS ROCOURT (Private Limited) - Liège

Dossier PHARMAPLUS ROCOURT, printed on 30 October 2026 from databakkes.be/en/0419680693/pharmaplus-rocourt. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMAPLUS ROCOURT from Liège, company number BE0419680693, closed financial year 2025 with a result of € 32,216 after tax. For that financial year PHARMAPLUS ROCOURT recorded a gross margin of € 290,836 and equity of € -28,859. Compared with financial year 2024, the result moved from € 3,454 to € 32,216. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 14, 2026.

What it is worth Caution

€ -28,859

▲ € 32,216 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 32,216

▲ € 28,762 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 24,128

▼ 46% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -47,859.

People and assets in 2025

Full-time equivalents

3.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 217,973

▲ 25% vs 2024

€ 66,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,648

▲ 269% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 177,014

▼ 27% vs 2024

€ 41,300 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 170,688

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,694

▲ 15% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 235,735 Gross margin 2022: € 235,735 First fiscal year in the series	€ 237,111 Gross margin 2023: € 237,111 ▲ 1% vs 2022 (€ 235,735) Favourable step	€ 220,080 Gross margin 2024: € 220,080 ▼ 7% vs 2023 (€ 237,111) Unfavourable step	€ 290,836 Gross margin 2025: € 290,836 ▲ 32% vs 2024 (€ 220,080) Favourable step	▲ 32%
Profit after taxes	€ 12,037 Profit after taxes 2022: € 12,037 First fiscal year in the series	€ 816 Profit after taxes 2023: € 816 ▼ 93% vs 2022 (€ 12,037) Unfavourable step	€ 3,454 Profit after taxes 2024: € 3,454 ▲ € 2,638 vs 2023 (€ 816) Favourable step	€ 32,216 Profit after taxes 2025: € 32,216 ▲ € 28,762 vs 2024 (€ 3,454) Favourable step	▲ € 28,762
Equity	€ -65,344 Equity 2022: € -65,344 First fiscal year in the series	€ -64,528 Equity 2023: € -64,528 ▲ € 816 vs 2022 (€ -65,344) Favourable step	€ -61,075 Equity 2024: € -61,075 ▲ € 3,454 vs 2023 (€ -64,528) Favourable step	€ -28,859 Equity 2025: € -28,859 ▲ € 32,216 vs 2024 (€ -61,075) Favourable step	▲ € 32,216
Total debts	€ 553,931 Total debts 2022: € 553,931 First fiscal year in the series	€ 532,182 Total debts 2023: € 532,182 ▼ 4% vs 2022 (€ 553,931) Favourable step	€ 526,367 Total debts 2024: € 526,367 ▼ 1% vs 2023 (€ 532,182) Favourable step	€ 428,896 Total debts 2025: € 428,896 ▼ 19% vs 2024 (€ 526,367) Favourable step	▼ 19%
Cash	€ 73,626 Cash 2022: € 73,626 First fiscal year in the series	€ 58,502 Cash 2023: € 58,502 ▼ 21% vs 2022 (€ 73,626) Unfavourable step	€ 44,772 Cash 2024: € 44,772 ▼ 23% vs 2023 (€ 58,502) Unfavourable step	€ 24,128 Cash 2025: € 24,128 ▼ 46% vs 2024 (€ 44,772) Unfavourable step	▼ 46%
Retained profit	€ -84,344 Retained profit 2022: € -84,344 First fiscal year in the series	€ -83,528 Retained profit 2023: € -83,528 ▲ € 816 vs 2022 (€ -84,344) Favourable step	€ -80,075 Retained profit 2024: € -80,075 ▲ € 3,454 vs 2023 (€ -83,528) Favourable step	€ -47,859 Retained profit 2025: € -47,859 ▲ € 32,216 vs 2024 (€ -80,075) Favourable step	▲ € 32,216
Bank debt	€ 275,238 Bank debt 2022: € 275,238 First fiscal year in the series	€ 224,032 Bank debt 2023: € 224,032 ▼ 19% vs 2022 (€ 275,238) Favourable step	€ 241,856 Bank debt 2024: € 241,856 ▲ 8% vs 2023 (€ 224,032) Unfavourable step	€ 177,014 Bank debt 2025: € 177,014 ▼ 27% vs 2024 (€ 241,856) Favourable step	▼ 27%
Balance sheet total	€ 488,587 Balance sheet total 2022: € 488,587 First fiscal year in the series	€ 467,654 Balance sheet total 2023: € 467,654 ▼ 4% vs 2022 (€ 488,587) Unchanged	€ 465,293 Balance sheet total 2024: € 465,293 ▼ 1% vs 2023 (€ 467,654) Unchanged	€ 400,037 Balance sheet total 2025: € 400,037 ▼ 14% vs 2024 (€ 465,293) Unchanged	▼ 14%
Employees (FTE)	2.7 Employees (FTE) 2022: 2.7 First fiscal year in the series	2.7 Employees (FTE) 2023: 2.7 Unchanged (2.7) Unchanged	3.3 Employees (FTE) 2024: 3.3 ▲ 0.6 vs 2023 (2.7) Unchanged	3.3 Employees (FTE) 2025: 3.3 Unchanged (3.3) Unchanged

Key figures of PHARMAPLUS ROCOURT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMAPLUS ROCOURT?

What happened at PHARMAPLUS ROCOURT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 14, 2026 New annual accounts for financial year 2025: profit of € 32,216 (▲ € 28,762 vs 2024). Source: NBB ↗
2026 PHARMA INVEST MANAGEMENT SRL stepped down as director. NBB
2008 PHARMA INVEST MANAGEMENT SRL became a director. NBB
Apr 1, 1979 New establishment in Liège. KBO
Mar 30, 1979 Start of the company according to the CBE. KBO

In short

From € 12,037 profit in 2022 to € 32,216 profit in 2025.

Best year ever: 2025, with € 32,216 profit.

On average € 88,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMA INVEST MANAGEMENT 98%

The stake of PHARMA INVEST MANAGEMENT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMAPLUS ROCOURT

The shares are held by PHARMA INVEST MANAGEMENT (98%).

Directors

According to the 2025 annual accounts

PHARMA INVEST MANAGEMENT SRL

Manager · represented by Hubert PIRENNE

Also active at: PHARMACIE ALLEUR, PHARMACIE HERSTAL, PHARMACIE SAINTE-WALBURGE

since 2008 · until 2026

Shareholders

PHARMA INVEST MANAGEMENT

98%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Tongres 431

4000 Liège

2.016.541.413

Place Reine-Astrid 2-4

4000 Liège

Active since 1 April 1979

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0419.680.693

VAT number

BE 0419.680.693

Registered office

Chaussée de Tongres 431, 4000 Liège

Names & denominations

PHARMAPLUS ROCOURT

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

30 March 1979

Peppol

Active · Active since 4 May 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMAPLUS ROCOURT

Warning lights

Financials

What happened to PHARMAPLUS ROCOURT?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions